IFM Investors’s Novavax NVAX Stock Holding History

IFM Investors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,096	Closed	-$817K	–	652
2022 Q1	$817K	Buy	11,096 +1,819	+20%	+$162K	0.01%	592
2021 Q4	$1.33M	Sell	9,277 -175	-2%	-$30.1K	0.02%	547
2021 Q3	$1.96M	Hold	9,452	–	–	0.04%	430
2021 Q2	$2.01M	Buy	+9,452	New	+$1.73M	0.04%	448

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IFM Investors's NVAX Position: Q2 2022 in Review

IFM Investors sold out of Novavax (NVAX) in Q2 2022, closing a stake of 11,096 shares — an estimated $817K sold.

IFM Investors first reported a position in NVAX in Q2 2021 and held it in 4 quarters. The position peaked at $2.01M in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

IFM Investors reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
IFM Investors sold 11,096 Novavax shares in Q2 2022, an estimated $817K.
IFM Investors first reported a position in Novavax in Q2 2021 and held it in 4 quarters.
IFM Investors's Novavax position peaked at $2.01M in Q2 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on IFM Investors's 13F filing for Q2 2022, filed 15 Jul 2022.